NCT06599229Active, not recruiting
Perfusion Abnormalities in Hypertrophic Cardiomyopathy
Myocardial Perfusion Abnormalities in Hypertrophic Cardiomyopathy
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 13 Sept 2024
- Start date
- 2 Jan 2025
- Primary completion date
- 30 May 2026
- Lead sponsor
- University of Virginia
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT06599229
What you commit to
- Study type: Observational
- Planned participants: 30
- From 2 Jan 2025 to the primary completion date, 30 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Allergy to ultrasound enhancing agent (lipid-stabilized) or regadenoson
- Moderate or greater reactive airways disease
Other
- Pregnancy
- Lactation
- Serious AE to regadenoson
- Hypotension
- Serious bradycardia not addressed by pacemaker
Who the study is looking for
- Diagnosis of hypertrophic cardiomyopathy
- Subject being initiated on clinically-indicated cardiac myosin inhibitor therapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Virginia Coordinator of this site? Confirm its status | Charlottesville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.